Hogea Cosmina, Van Effelterre Thierry, Cassidy Adrian
GlaxoSmithKline Vaccines, 2301 Renaissance Blvd Ste RN0510, King of Prussia, PA, USA.
BMC Infect Dis. 2014 May 28;14:291. doi: 10.1186/1471-2334-14-291.
Over the past decade, there has been sustained interest and efforts to develop a S. aureus vaccine. There is a need to better evaluate the potential public health impact of S. aureus vaccination, particularly given that preventative measures exist to reduce infection. To our knowledge, there is no previous work to assess the potential of a S. aureus vaccine to yield additional MRSA infection reduction in a hospital setting, on top of other preventative measures that already proved efficient.
The main objectives were to propose a versatile simulation framework for assessing potential added benefits of a hypothetical S. Aureus vaccine in conjunction with other preventative measures, and to illustrate possibilities in a given hospital setting. To this end, we employed a recently published dynamic transmission modelling framework that we further adapted and expanded to include a hypothetical S. aureus vaccination component in order to estimate potential benefits of vaccinating patients prior to hospital admission.
Model-based projections indicate that even with other hygiene prevention measures in place, vaccination of patients prior to hospital admission has the potential to provide additional reduction of MRSA infection. Vaccine coverage and vaccine efficacy are key factors that would ultimately impact the magnitude of this reduction. For example, in an average case scenario with 50% decolonization, 50% screening and 50% hygiene compliance level in place, S. aureus vaccination with 25% vaccine coverage, 75% vaccine efficacy against infection, and 0% vaccine efficacy against colonization, may lead to 12% model-projected additional reduction in MRSA infection prevalence due to vaccination, while this reduction could reach 37% for vaccination with 75% vaccine coverage and 75% vaccine efficacy against infection in the same average case scenario.
S. aureus vaccination could potentially provide additional reduction of MRSA infection in a hospital setting, on top of reductions from hygiene prevention measures. The magnitude of such additional reductions can vary significantly depending on the level of hygiene prevention measures in place, as well as key vaccine factors such as coverage and efficacy. Identifying appropriate combinations of preventative measures may lead to optimal strategies to effectively reduce MRSA infection in hospitals.
在过去十年中,人们一直持续关注并致力于研发金黄色葡萄球菌疫苗。鉴于已存在预防感染的措施,有必要更好地评估金黄色葡萄球菌疫苗对公共卫生的潜在影响。据我们所知,此前尚无研究评估在医院环境中,除已证明有效的其他预防措施外,金黄色葡萄球菌疫苗额外降低耐甲氧西林金黄色葡萄球菌(MRSA)感染的潜力。
主要目标是提出一个通用的模拟框架,以评估假设的金黄色葡萄球菌疫苗与其他预防措施相结合的潜在附加益处,并在特定医院环境中说明其可能性。为此,我们采用了最近发表的动态传播建模框架,并对其进行了进一步调整和扩展,纳入了假设的金黄色葡萄球菌疫苗接种部分,以估计在患者入院前进行疫苗接种的潜在益处。
基于模型的预测表明,即使已采取其他卫生预防措施,在患者入院前进行疫苗接种仍有可能进一步降低MRSA感染。疫苗接种覆盖率和疫苗效力是最终影响这种降低幅度的关键因素。例如,在一个平均病例场景中,去定植率为50%、筛查率为50%、卫生合规率为50%,接种覆盖率为25%、疫苗抗感染效力为75%且抗定植效力为0%的金黄色葡萄球菌疫苗接种,可能导致模型预测的因接种疫苗而使MRSA感染患病率额外降低12%,而在相同平均病例场景中,接种覆盖率为75%且疫苗抗感染效力为75%时,这种降低幅度可能达到37%。
在医院环境中,除卫生预防措施所带来的感染降低外,金黄色葡萄球菌疫苗接种可能进一步降低MRSA感染。这种额外降低的幅度会因现有卫生预防措施的水平以及疫苗接种覆盖率和效力等关键疫苗因素而有显著差异。确定预防措施的适当组合可能会产生有效降低医院内MRSA感染的最佳策略。